TABLE 1.

In vitro susceptibilities of Cryptococcus isolates to amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole according to origin and underlying disease of patients

Origin (no. of strains)	Antifungal agent	MIC (μg/ml)
		Range	50%	90%
Environmental (45)	Amphotericin B	0.016-0.5	0.25	0.5
	Flucytosine	0.5-64	4	8
	Fluconazole	0.25-64	4	8
	Itraconazole	0.016-0.5	0.063	0.25
	Voriconazole	0.016-0.25	0.063	0.25
	Posaconazole	0.016-0.125	0.31	0.63
	Isavuconazole	0.002-0.031	0.004	0.016
Clinical (117)	Amphotericin B	0.031-1	0.25	0.25
	Flucytosine	0.063-8	4	8
	Fluconazole	0.25-8	2	4
	Itraconazole	0.016-1	0.031	0.25
	Voriconazole	0.016-0.25	0.031	0.125
	Posaconazole	0.016-0.5	0.004	0.016
	Isavuconazole	0.002-0.063	0.004	0.016
AIDS patients (85)	Amphotericin B	0.031-1	0.25	0.25
	Flucytosine	0.125-8	4	8
	Fluconazole	0.25-8	2	2
	Itraconazole	0.016-0.5	0.031	0.125
	Voriconazole	0.016-0.25	0.031	0.125
	Posaconazole	0.016-0.125	0.031	0.125
	Isavuconazole	0.002-0.063	0.008	0.016
Non-AIDS patients	Amphotericin B	0.125-1	0.25	1
(32)	Flucytosine	0.063-8	2	4
	Fluconazole	0.25-8	2	8
	Itraconazole	0.016-1	0.031	0.063
	Voriconazole	0.016-0.25	0.063	0.063
	Posaconazole	0.016-0.5	0.063	0.125
	Isavuconazole	0.004-0.063	0.008	0.031
Total	Amphotericin B	0.016-1	0.25	0.25
	Flucytosine	0.063-64	4	8
	Fluconazole	0.25-64	2	4
	Itraconazole	0.016-1	0.031	0.25
	Voriconazole	0.016-0.25	0.031	0.125
	Posaconazole	0.002-0.125	0.004	0.016
	Isavuconazole	0.002-0.063	0.004	0.016

^a50% and 90%, MIC₅₀ and MIC₉₀, respectively.